Italia markets closed

ProQR Therapeutics N.V. (PRQR)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,2899-0,0901 (-3,79%)
Alla chiusura: 04:00PM EDT
2,2100 -0,08 (-3,49%)
Dopo ore: 07:58PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3800
Aperto2,4100
Denaro2,2300 x 200
Lettera2,2700 x 200
Min-Max giorno2,2300 - 2,4700
Intervallo di 52 settimane1,1100 - 3,2900
Volume106.239
Media Volume312.521
Capitalizzazione186,294M
Beta (5 anni mensile)0,19
Rapporto PE (ttm)N/D
EPS (ttm)-0,3800
Prossima data utili14 mag 2024 - 20 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,18
  • GlobeNewswire

    ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 a

  • GlobeNewswire

    ProQR Therapeutics Provides Update on Ophthalmic Assets

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology

  • GlobeNewswire

    ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference. A webcast of the Company’s presentation will be available from the “Investors & Media” section of ProQR’s website un